GoAI
Get started
MicroTech Medical (Hangzhou) Co., Ltd. logo

MicroTech Medical (Hangzhou) Co., Ltd.

2235.HK

HKSEHealthcareMedical - Devices

Open in GoAI

Latest quote

HK$6.92

−HK$0.23 · -3.22%

Aug 24, 11:59 AM HKT

2235.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

MicroTech Medical (Hangzhou) Co., Ltd. focuses on the innovation, production, and market distribution of essential medical devices and consumables for diabetes management. Its operations extend across the People's Republic of China and into global markets. The company offers a comprehensive range of products, including the Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, traditional blood glucose monitoring systems, and advanced closed-loop artificial pancreas technology. Beyond its core offerings, MicroTech Medical is also actively involved in engineering and technological research, experimentation, and developmental endeavors. The firm, established in 2011, maintains its headquarters in Hangzhou, People's Republic of China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Pan Zheng
Listed since
Oct 19, 2021
Employees
664

Market position

Day range

Current HK$6.92

52-week range

Current HK$6.92

Open
HK$7.135
Previous close
HK$7.15
Volume
47.2K
0.63× average
Average volume
74.93K
Average daily volume
Market cap
2.86B HKD
Beta
0.49
Market reference 1
50-day average
HK$7.1244
-2.87% below average
200-day average
HK$7.3402
-5.72% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.44B CNY
P/E (TTM)
28.91×
P/B (TTM)
1.23×
P/S (TTM)
2.98×
EV / EBITDA
49.76×
Earnings yield
1.40%
Free cash flow yield
-0.21%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
56.61%
Operating margin
10.52%
Net margin
9.98%
Return on equity
1.99%
Return on assets
1.74%
Return on invested capital
2.06%

Financial health

Debt / equity
0.05×
Current ratio
6.39×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends65%23%-19%-61%Gross margin, FY2021: 46.82%Gross margin, FY2022: 45.90%Gross margin, FY2023: 49.62%Gross margin, FY2024: 52.91%Gross margin, FY2025: 54.09%Operating margin, FY2021: -39.74%Operating margin, FY2022: -18.55%Operating margin, FY2023: -48.43%Operating margin, FY2024: -18.07%Operating margin, FY2025: 6.65%Net margin, FY2021: -31.82%Net margin, FY2022: -20.19%Net margin, FY2023: -50.34%Net margin, FY2024: -18.26%Net margin, FY2025: 6.08%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.82%. Gross margin FY2022 45.90%. Gross margin FY2023 49.62%. Gross margin FY2024 52.91%. Gross margin FY2025 54.09%. Operating margin FY2021 -39.74%. Operating margin FY2022 -18.55%. Operating margin FY2023 -48.43%. Operating margin FY2024 -18.07%. Operating margin FY2025 6.65%. Net margin FY2021 -31.82%. Net margin FY2022 -20.19%. Net margin FY2023 -50.34%. Net margin FY2024 -18.26%. Net margin FY2025 6.08%.

Income trends

Revenue

660.79M CNY+91.19%

Operating income

43.97M CNY+106.43M CNY

Net income

40.15M CNY+103.27M CNY
Income trends across reported periods739.37M CNY425.05M CNY110.73M CNY−203.6M CNYRevenue, FY2021: 151.4M CNYRevenue, FY2022: 173.54M CNYRevenue, FY2023: 248.35M CNYRevenue, FY2024: 345.62M CNYRevenue, FY2025: 660.79M CNYOperating income, FY2021: −60.17M CNYOperating income, FY2022: −32.19M CNYOperating income, FY2023: −120.27M CNYOperating income, FY2024: −62.46M CNYOperating income, FY2025: 43.97M CNYNet income, FY2021: −48.18M CNYNet income, FY2022: −35.04M CNYNet income, FY2023: −125.02M CNYNet income, FY2024: −63.12M CNYNet income, FY2025: 40.15M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 151.4M CNY. Revenue FY2022 173.54M CNY. Revenue FY2023 248.35M CNY. Revenue FY2024 345.62M CNY. Revenue FY2025 660.79M CNY. Operating income FY2021 −60.17M CNY. Operating income FY2022 −32.19M CNY. Operating income FY2023 −120.27M CNY. Operating income FY2024 −62.46M CNY. Operating income FY2025 43.97M CNY. Net income FY2021 −48.18M CNY. Net income FY2022 −35.04M CNY. Net income FY2023 −125.02M CNY. Net income FY2024 −63.12M CNY. Net income FY2025 40.15M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue660.79M CNY345.62M CNY248.35M CNY173.54M CNY151.4M CNY
Cost of goods sold303.36M CNY162.77M CNY125.13M CNY93.89M CNY80.52M CNY
Gross profit357.42M CNY182.85M CNY123.22M CNY79.66M CNY70.88M CNY
Research and development76.34M CNY76.56M CNY70.1M CNY30.6M CNY14.82M CNY
Selling, general, and administrative170.02M CNY151.73M CNY161.52M CNY158.99M CNY94.27M CNY
Operating expenses313.45M CNY242.6M CNY243.49M CNY197.89M CNY131.05M CNY
Interest income46.54M CNY62.84M CNY68.24M CNY55.72M CNY23.32M CNY
Interest expense446.05K CNY676.45K CNY313.19K CNY147K CNY17K CNY
Depreciation and amortization11.2M CNY10.37M CNY11.17M CNY10.15M CNY8.33M CNY
Operating income43.97M CNY−62.46M CNY−120.27M CNY−32.19M CNY−60.17M CNY
Net income40.15M CNY−63.12M CNY−125.02M CNY−35.04M CNY−48.18M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.1
FY2025
Latest fiscal-year revenue
660.79M CNY
FY2025 · +91.19% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.14-0.02-0.17-0.33FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend711.73M507.97M304.22M100.47MFY21FY22FY23FY24FY25

2235.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 2235.HK

research.disclaimer